Anesthesia

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 191 person Asked by .

bookmark_add

Coagulation Disorders & Transfusion in the ICU

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

CRITICAL

1	Disseminated Intravascular Coagulation (DIC): simultaneous pathological activation of coagulation AND fibrinolysis. ISTH DIC Score: platelets, PT, fibrinogen, D-dimer — score ≥5 = overt DIC. Causes: sepsis (most common in ICU), trauma, obstetric catastrophe (abruption, AFE), malignancy, transfusion reactions, snake envenomation. Treatment is of the underlying cause; blood products are given for bleeding or procedural coverage, not to correct laboratory values alone.
2	Transfusion thresholds in ICU: Restrictive strategy (Hb 7 g/dL) is equivalent or superior to liberal (Hb 10 g/dL) in most ICU patients — TRICC trial. Exceptions where higher thresholds are used: active ACS (Hb <8–10), subarachnoid haemorrhage (Hb <8–9). Transfusion-Related Acute Lung Injury (TRALI): non-cardiogenic pulmonary oedema within 6 hours of transfusion — donor antibodies (anti-HLA, anti-neutrophil) activate recipient neutrophils in lungs. Leading cause of transfusion-related mortality. Treatment: supportive (may require mechanical ventilation).
3	Massive Haemorrhage Protocol (MHP): defined as transfusion of ≥10 units pRBC in 24h, or ≥4 units in 1h. Damage control resuscitation: balanced blood product ratio (pRBC : FFP : platelets = 1:1:1 — PROPPR trial); permissive hypotension (SBP 80–90 until surgical haemostasis); early tranexamic acid (CRASH-2: within 3 hours of injury, reduces mortality in haemorrhagic trauma — 1g IV over 10 min, then 1g over 8h); avoid hypothermia, acidosis, hypocalcaemia (lethal triad).
4	Viscoelastic haemostatic assays (VHA): ROTEM (Rotational Thromboelastometry) and TEG (Thromboelastography) provide real-time analysis of clot formation, strength, and lysis — allowing targeted, goal-directed transfusion rather than empirical product replacement. ITACTIC trial: VHA-guided transfusion did not reduce mortality vs conventional coagulation-guided transfusion in trauma — but reduced exposure to FFP and platelets. VHA is most valuable in cardiac surgery, liver transplantation, and massive haemorrhage.
5	Heparin-Induced Thrombocytopenia (HIT): immune-mediated platelet activation by anti-PF4/heparin antibodies. Platelet fall 50% or to <100 × 10⁹/L, days 5–14 of heparin exposure (or immediate re-exposure). Paradoxical thrombosis risk (not bleeding) despite thrombocytopenia. 4T score assesses pre-test probability. Management: stop all heparin immediately (including flushes, heparin-coated catheters); initiate non-heparin anticoagulant — argatroban (hepatic metabolism, preferred in renal failure), fondaparinux, bivalirudin. Warfarin contraindicated acutely (risk of venous gangrene via protein C depletion).

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 192 person Asked by .

bookmark_add

Nutrition in the Critically Ill Patient

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

CLINICAL

1	When to start nutrition: early enteral nutrition (EN) within 24–48 hours of ICU admission is recommended (ESPEN, ASPEN) — reduces infectious complications, maintains gut mucosal integrity, and prevents bacterial translocation. Enteral is preferred over parenteral — preserves gut-associated lymphoid tissue (GALT), supports the gut-immune axis, and is associated with fewer complications and lower cost. Parenteral nutrition (PN): reserved for EN contraindicated or intolerant (ileus, GI fistula, short bowel) — start after day 7 in well-nourished patients (EPaNIC trial: early PN increased infections and ICU stay).
2	Caloric targets: acute phase (days 1–3): trophic/hypocaloric feeding 400–800 kcal/day — full feeding in early acute phase does not improve outcomes and may worsen autophagy (PERMIT, TARGET trials). Late phase: advance to 25–30 kcal/kg/day. Protein: 1.2–2.0 g/kg/day (higher in hypermetabolic states: burns, trauma, AKI on CRRT — 2.0–2.5 g/kg/day). Indirect calorimetry (gold standard for caloric needs) is preferred over weight-based equations when available.
3	Refeeding syndrome: in severely malnourished patients, initiating nutrition causes rapid cellular uptake of phosphate, potassium, and magnesium → profound hypophosphataemia (PO₄ <0.5 mmol/L), hypokalaemia, hypomagnesaemia → cardiac arrhythmia, respiratory failure, Wernicke's encephalopathy, haemolytic anaemia, rhabdomyolysis. Prevention: identify high-risk patients (BMI <16, weight loss >15%, minimal intake >10 days); start feeding at 10 kcal/kg/day; supplement phosphate, potassium, magnesium, and thiamine 200–300 mg TDS before starting nutrition.
4	Gastric residual volume (GRV): GRV monitoring is no longer recommended as a routine guide to EN tolerance — NUTRIREA-2 and other trials showed GRV <500 mL without signs of intolerance should not prompt withholding feeds. Prokinetics (metoclopramide, erythromycin) are used for gastroparesis/high GRV with clinical signs of intolerance. Post-pyloric feeding (nasojejunal tube) reduces pulmonary aspiration risk in high-risk patients (GCS <9, prone positioning, recurrent aspiration).

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 193 person Asked by .

bookmark_add

Multi-Organ Dysfunction Syndrome (MODS)

description Clinical Response

CRITICAL

1	MODS: progressive, potentially reversible dysfunction of ≥2 organ systems, arising from acute illness — represents the final common pathway of critically ill patients regardless of initial insult. SOFA score quantifies MODS: assesses respiration (P/F ratio), coagulation (platelets), liver (bilirubin), cardiovascular (vasopressor dose and MAP), CNS (GCS), renal (creatinine/UO). SOFA ≥2 = organ dysfunction. Maximum SOFA score correlates with ICU mortality: SOFA 2–7: ~33%; 8–11: ~50%; ≥12: ~95%.
2	Pathophysiology: the two-hit model — first hit (trauma, surgery, burns) primes innate immune system; second hit (infection, ischaemia-reperfusion) triggers exaggerated inflammatory response with systemic endothelial activation, microvascular thrombosis, impaired mitochondrial O₂ utilisation (cytopathic hypoxia — oxygen is available but cells cannot use it), and apoptosis of parenchymal cells. This explains why targeting supranormal DO₂ fails — the problem is not delivery but utilisation.
3	Acute Hepatic Dysfunction in MODS: bilirubin >2 mg/dL (SOFA criterion). Hypoxic hepatitis (ischaemic hepatitis/"shock liver"): dramatic transaminase rise (AST/ALT >1000 IU/L) with low hepatic blood flow — reverses with restoration of perfusion. Sepsis-associated liver dysfunction: cholestatic pattern, jaundice without major transaminase elevation. Acute liver failure criteria: coagulopathy (INR >1.5) + encephalopathy within 26 weeks in a patient without prior liver disease.
4	Abdominal Compartment Syndrome (ACS): sustained intra-abdominal pressure (IAP) >20 mmHg with new organ dysfunction. Normal IAP 0–5 mmHg; intra-abdominal hypertension (IAH) IAP ≥12 mmHg. IAP measured via bladder catheter with 25 mL saline instilled — transducer zeroed at mid-axillary line. ACS causes: ↓cardiac output (IVC compression ↓preload; diaphragm elevation ↑intrathoracic pressure ↑RV afterload), ↑airway pressures (ventral displacement of diaphragm), AKI (renal vein compression + ↑renal compartment pressure), bowel ischaemia. Management: medical (NG decompression, diuresis, neuromuscular blockade) → surgical decompressive laparotomy for refractory cases.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 194 person Asked by .

bookmark_add

ICU-Acquired Infections & Antibiotic Stewardship

description Clinical Response

GUIDELINE

1	Ventilator-Associated Pneumonia (VAP): pneumonia developing ≥48h after intubation. Most common ICU-acquired infection in mechanically ventilated patients. Prevention bundle (VAP bundle): head-of-bed elevation 30–45°; daily sedation breaks; oral chlorhexidine decontamination; subglottic secretion drainage; early weaning assessment; avoidance of unnecessary PPIs (↑risk of aspiration of gastric bacteria). VAP reduces ventilator-free days and increases ICU mortality — bundle adherence significantly reduces VAP rates.
2	Central Line-Associated Bloodstream Infection (CLABSI): prevention — maximal sterile barrier precautions during insertion (cap, mask, sterile gown, gloves, full-body drape); chlorhexidine skin preparation; subclavian vein preferred (lowest infection risk); avoid femoral route; daily review of line necessity; chlorhexidine-impregnated dressings; antimicrobial-coated catheters in high-risk settings. Remove CVC as soon as no longer needed — each additional day of catheter = 0.1–0.4% additional infection risk.
3	Catheter-Associated UTI (CAUTI): most common healthcare-associated infection. Prevention: insert only when indicated; use closed drainage system; periurethral hygiene; maintain unobstructed flow; remove catheter as soon as possible. Bacteriuria without symptoms should NOT be treated (asymptomatic bacteriuria) — except in pregnant women and pre-urological procedure. Diagnosis requires >10⁵ CFU/mL PLUS symptoms or systemic signs of infection.
4	Antibiotic stewardship principles: De-escalation based on culture results — narrow spectrum once pathogen identified. Duration: 7 days for most ICU infections (including VAP — PRORATA trial); 5 days for uncomplicated pneumonia in stable patients. Procalcitonin (PCT)-guided therapy: PCT falls with resolution of bacterial infection; PCT-guided discontinuation reduces antibiotic duration without worsening outcomes (PRORATA, SAPS trials). PCT poorly specific for viral vs bacterial in isolation — interpret with clinical context.
5	Candida infections in ICU: risk factors — prolonged broad-spectrum antibiotics, TPN, renal replacement therapy, prior surgery, immunosuppression. Candida score (CS): total parenteral nutrition (1pt) + surgery (1pt) + multifocal Candida colonisation (1pt) + sepsis (2pt) — CS ≥3 predicts candidaemia; consider antifungal prophylaxis. Treatment: echinocandins (anidulafungin, caspofungin, micafungin) are first-line for invasive candidiasis in critically ill — superior to fluconazole in unstable patients and for C. glabrata/C. krusei (which have inherent fluconazole resistance).

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 195 person Asked by .

bookmark_add

Neurological Monitoring & Brain Death

description Clinical Response

MONITORING

1	Intracranial Pressure (ICP) Monitoring: indicated in severe TBI (GCS ≤8 + CT abnormality, or GCS ≤8 + CT normal with ≥2 of: age >40, BP <90, motor posturing). Normal ICP <10 mmHg; ICP >20 mmHg for >5 minutes requires treatment. CPP (cerebral perfusion pressure) = MAP − ICP; target CPP 60–70 mmHg. ICP measured via intraventricular catheter (gold standard — also allows CSF drainage as ICP treatment) or intraparenchymal monitor (Codman). Lundberg waves: A waves (plateau waves, ICP 50–100 for >5 min) = severely impaired compliance; B waves = normal variants.
2	ICP management ladder: Tier 1 — head of bed 30°, midline head position, adequate sedation/analgesia, normothermia, normoxia, normocapnia (PaCO₂ 35–40), normonatraemia or mild hypernatraemia, glucose 140–180. Tier 2 — osmotherapy: mannitol 0.25–1 g/kg (osmotic diuresis, plasma expansion, rheological effects; contraindicated if hypovolaemic); hypertonic saline (3% or 23.4%) — preferred in hypovolaemia, raises serum Na to 145–155. Tier 3 — CSF drainage, decompressive craniectomy (DECRA, RESCUEicp), barbiturate coma, hypothermia.
3	Targeted Temperature Management (TTM): post-cardiac arrest — TTM 32–36°C for 24 hours was previously standard (TTM trial 2013: 33°C vs 36°C — no difference in outcome). TTM-2 trial (2021): normothermia (37.5°C) with active fever prevention equivalent to TTM-33°C — guidelines now recommend fever prevention (<37.8°C) rather than mandatory hypothermia. Hypothermia in TBI: Eurotherm3235 trial showed hypothermia ↑mortality and disability in TBI — NOT recommended for ICP control.
4	Brain Death (Death by Neurological Criteria — DNC): irreversible loss of all brain and brainstem function. Prerequisites: known structural cause, exclusion of reversible causes (hypothermia <36°C, drug intoxication, metabolic derangement, neuromuscular blockade). Clinical testing: coma, absent brainstem reflexes (pupillary, corneal, oculocephalic, oculovestibular, gag, cough), and apnoea test (PaCO₂ rise to ≥60 mmHg, or 20 mmHg above baseline, with no respiratory effort — positive test confirms brain death). Two clinicians (one senior) must confirm; confirmation studies (EEG, cerebral angiography, TCD) used if clinical testing cannot be completed.
5	Prognostication after cardiac arrest: multimodal approach at ≥72h post-cardiac arrest (later if TTM used). Poor prognostic markers: absent pupillary light reflex at 72h; absent N20 SSEP cortical response; burst suppression or suppressed EEG; NSE (neuron-specific enolase) >60 mcg/L at 48–72h; diffuse anoxic injury on CT/MRI (loss of grey-white differentiation, GWR <1.22). No single test is reliable alone — ERC/EAN 2021 guidelines mandate multimodal assessment before withdrawal of life-sustaining treatment.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 196 person Asked by .

bookmark_add

Cardiovascular Emergencies in the ICU

description Clinical Response

CRITICAL

1	Cardiogenic shock (CS): cardiac output inadequate to meet tissue demands despite adequate preload. CS complicating AMI: mortality 40–50%. IABP-SHOCK II trial: intra-aortic balloon pump did NOT reduce 30-day mortality in AMI-CS — IABP is no longer routinely recommended. Impella (axial flow pump): IMPRESS in Severe SHOCK trial — no benefit over IABP; RECOVR AMI trial ongoing. ECMO (VA-ECMO): ECLS-SHOCK trial (2023) — VA-ECMO did NOT improve 30-day mortality in AMI-CS vs medical management, but reduced use of additional MCS. Early coronary revascularisation remains the cornerstone of AMI-CS management.
2	Massive Pulmonary Embolism: haemodynamic instability (SBP <90 or drop >40 mmHg for >15 min). RV strain on ECG (S1Q3T3, right bundle branch block, sinus tachycardia), echo (D-sign — interventricular septal shift toward LV, RV dilation/hypokinesia). Systemic thrombolysis (alteplase 100 mg over 2h) is indicated for high-risk PE with CS — reduces haemodynamic compromise but increases major bleeding (including intracranial haemorrhage 3%). Contraindications: recent surgery/stroke/trauma. Catheter-directed thrombolysis (CDT) or surgical embolectomy for absolute contraindications to systemic lysis.
3	Cardiac Tamponade: Beck's triad (hypotension, elevated JVP, muffled heart sounds) is present in <30% of cases — triad has poor sensitivity. Pulsus paradoxus >10 mmHg (exaggerated inspiratory fall in SBP) — occurs because RV expands into constrained pericardial space, compressing LV during inspiration. Echo: RA/RV collapse in diastole (earliest sign), IVC plethora. Pericardiocentesis is life-saving — guided by echo (subxiphoid approach). Do NOT initiate positive pressure ventilation before decompression in suspected tamponade — PPV abolishes pulsus paradoxus and can precipitate cardiovascular collapse by further reducing venous return.
4	Hypertensive Emergency: severe hypertension (typically SBP >180/DBP >120) with evidence of acute end-organ damage (encephalopathy, stroke, aortic dissection, acute HF, AKI, MAHA, eclampsia). Distinguish from hypertensive urgency (no end-organ damage). Target: reduce MAP by no more than 25% in the first hour — rapid BP reduction risks cerebral/coronary hypoperfusion. Agents: nicardipine or clevidipine infusion (titratable CCB) for most; labetalol infusion in aortic dissection (target SBP <120 within 20 min); sodium nitroprusside (risk of cyanide toxicity with prolonged use); hydralazine (less titratable, avoid in aortic dissection).

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 197 person Asked by .

bookmark_add

Common Poisoning & Drug Overdose Management

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

CLINICAL

1	Toxidromes — pattern recognition is exam-critical: Sympathomimetic (cocaine, amphetamines): ↑HR, ↑BP, mydriasis, hyperthermia, agitation, diaphoresis. Anticholinergic (TCAs, antihistamines, atropine): "mad as a hatter, blind as a bat, dry as a bone, hot as a hare, red as a beet" — hyperthermia, dry flushed skin, urinary retention, mydriasis, ileus. Cholinergic (organophosphates): SLUDGE — Salivation, Lacrimation, Urination, Defaecation, GI cramps, Emesis + bronchospasm, bradycardia, miosis. Opioid: miosis, CNS/respiratory depression, ↓BP, ↓bowel sounds.
2	Organophosphate poisoning: irreversible inhibition of acetylcholinesterase → ACh accumulation at muscarinic and nicotinic receptors. Management: Atropine — titrate to drying of secretions (not HR or pupil size); may need massive doses (2 mg IV every 5–10 min, up to hundreds of mg). Pralidoxime (2-PAM): reactivates cholinesterase if given within 24–48h (before "ageing" of the enzyme-OP bond). Benzodiazepines for seizures. Intubation for respiratory failure — succinylcholine prolonged paralysis risk (plasma cholinesterase inhibited); use rocuronium instead.
3	Paracetamol (acetaminophen) overdose: hepatotoxicity via NAPQI (N-acetyl-p-benzoquinone imine) accumulation when glutathione depleted. Rumack-Matthew nomogram: plot serum level at 4h post-ingestion to determine NAC treatment necessity. N-acetylcysteine (NAC): replenishes glutathione; effective if given within 8–10 hours (optimal); some benefit up to 24h. IV protocol: 150 mg/kg over 60 min, then 50 mg/kg over 4h, then 100 mg/kg over 16h. Indication for liver transplant: King's College Criteria — pH <7.3, or INR >6.5 + creatinine >300 + grade III–IV encephalopathy.
4	Tricyclic Antidepressant (TCA) overdose: sodium channel blockade (QRS ≥100–120 ms → ventricular arrhythmia, seizures), α-blockade (hypotension), anticholinergic effects. Management: sodium bicarbonate (1–2 mEq/kg IV) — alkalinisation and sodium loading reverses sodium channel blockade; target pH 7.45–7.55. Avoid physostigmine. Avoid class IA/IC antiarrhythmics (worsen sodium channel blockade). Intralipid considered for refractory cardiac toxicity. Seizures: benzodiazepines first-line; phenytoin is ineffective in TCA seizures.
5	Decontamination in ICU: activated charcoal 1 g/kg orally/NGT — effective if given within 1–2 hours of ingestion for most poisons (not effective for iron, lithium, alcohols, caustics, hydrocarbons). Multiple-dose activated charcoal (MDAC): enhances elimination of carbamazepine, theophylline, quinine, phenobarbital, dapsone. Gastric lavage: rarely used — only within 1 hour of life-threatening ingestion. Whole bowel irrigation (PEG solution 1–2 L/h): for sustained-release/enteric-coated tablets, body packers, lithium, iron. Urinary alkalinisation: for salicylate and phenobarbital overdose (enhances renal elimination by ion trapping).

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 198 person Asked by .

bookmark_add

End-of-Life Care & Ethical Decision-Making in ICU

description Clinical Response

GUIDELINE

1	Withholding vs withdrawing life-sustaining treatment (LST): ethically and legally equivalent — both require the same justification (disproportionate burden vs benefit, consistent with patient values). Withdrawing treatment is NOT euthanasia — it allows the natural disease process to proceed. Doctrine of Double Effect: administering medications (opioids, benzodiazepines) to relieve suffering, with the foreseen but unintended consequence of potentially hastening death, is ethically permissible — the intention is comfort, not death.
2	Futility: a treatment is futile when it offers no reasonable expectation of benefit — quantitative futility (treatment fails in 100 consecutive similar cases), qualitative futility (treatment cannot achieve an acceptable quality of life for the patient). Physicians are not obligated to offer or provide treatments that are futile. Best interests standard: used when a patient lacks decision-making capacity and no advance directive exists — surrogate decision-makers (family) act in what they believe the patient would have wanted ("substituted judgment"), NOT what the family wants.
3	Palliative care in the ICU: not synonymous with end-of-life — early integration of palliative care alongside curative treatment improves symptom control, reduces family distress, and can improve survival (Temel 2010 in lung cancer). Goals-of-care conversations should occur within 72h for patients at high risk of ICU death. Family communication: VALUE mnemonic — Value family statements; Acknowledge family emotions; Listen to the family; Understand the patient as a person; Elicit family questions.
4	Terminal weaning (ventilator withdrawal): the most common method of LST withdrawal in mechanically ventilated patients. Adequate analgesia (morphine) and anxiolysis (midazolam/lorazepam) must be ensured before and during withdrawal — titrate to comfort, not to a target ventilatory parameter. Two approaches: immediate extubation (preferred in many centres — more natural) vs gradual wean. ICU bereavement care: post-ICU family support reduces complicated grief and PTSD in bereaved relatives.
5	Organ donation after brain death (DBD) and after circulatory death (DCD): anaesthesiologists play a key role in donor management. Physiological consequences of brain death: haemodynamic instability (catecholamine storm followed by vasodilation), diabetes insipidus (loss of ADH — manage with vasopressin/DDAVP + fluid replacement), neurogenic pulmonary oedema, hypothermia, coagulopathy. Donor management targets: MAP 60–80, CVP 6–10, UO 1–3 mL/kg/h, normoglycaemia, normothermia, PaO₂ >100 mmHg, methylprednisolone 15 mg/kg (lung protection). Maximising organ utilisation is a professional obligation.

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 199 person Asked by .

bookmark_add

Discuss the physiological regulation of CBF, BBB structure/breakdown in neuro-trauma, ICP factors, ICP-lowering pharmacology, and SjO2 monitoring.

description Clinical Response

"

Q1 · PAPER I · 10 MARKS

Cerebral Blood Flow, Intracranial Pressure & the Monro-Kellie Doctrine

AIIMS · PAPER I — APPLIED BASIC SCIENCES [10 MARKS]

Discuss the physiological regulation of CBF, BBB structure/breakdown in neuro-trauma, ICP factors, ICP-lowering pharmacology, and SjO2 monitoring.

⚙ Core Concept

Normal CBF ~50 mL/100g/min (grey matter 80, white matter 20). CBF is held constant across MAP 60-150 mmHg by autoregulation (myogenic, metabolic, neurogenic, endothelial). Outside this range CBF becomes pressure-passive - the single most exam-relevant concept in neuroanesthesia.

A. Physiological Regulation of CBF

Mechanism	Basis	Clinical Relevance
Pressure autoregulation (myogenic)	Vascular smooth muscle constricts/dilates with transmural pressure (Bayliss effect)	Maintains flat CBF curve 60-150 mmHg; impaired in TBI, ischemia
Metabolic (flow-metabolism coupling)	CBF tracks CMRO2; adenosine, K+, H+ cause local vasodilation	Basis of functional imaging; burst-suppression reduces CBF
Chemical - PaCO2	CBF changes ~3-4%/mmHg PaCO2 (20-80 mmHg) via perivascular pH	Hyperventilation (PaCO2 30) acutely lowers ICP; effect wanes over 6-24h
Chemical - PaO2	Unchanged until PaO2 <50-60 mmHg, then steep vasodilation	Hypoxia is a potent, late-acting cerebral vasodilator
Neurogenic	Sympathetic/parasympathetic innervation of larger vessels	Minor role; modulates autoregulation curve
Endothelial	NO (dilator) vs endothelin-1 (constrictor) balance	Volatiles impair endothelial autoregulation dose-dependently

Autoregulation curve: flat plateau 60-150 mmHg -> below 60 pressure-passive ischemia risk -> above 150 forced dilation, vasogenic edema/hemorrhage risk. Curve shifts right in chronic hypertension and is lost/flattened in TBI, severe hypoxia, high volatile concentrations.

B. Blood-Brain Barrier - Structure & Breakdown

Endothelial tight junctions (claudin-5, occludin, ZO-1) - principal anatomical basis of BBB
Basement membrane - continuous, non-fenestrated
Pericytes - regulate permeability and angiogenesis
Astrocytic end-feet - ensheath >99% of capillary surface
Efflux transporters (P-glycoprotein) exclude lipophilic xenobiotics

Functional: permits small lipophilic molecules by diffusion; excludes ionized/polar molecules unless actively transported (GLUT-1, LAT-1).

BBB Breakdown in Acute Neuro-Trauma

Mechanical disruption of tight junctions + MMP-9 degradation of basement membrane -> vasogenic edema. Secondary cascade: glutamate excitotoxicity -> astrocyte swelling -> cytotoxic edema. Biphasic breakdown - immediate (mechanical) and delayed (4-6h, inflammatory) - the delayed phase is a therapeutic window for steroids/hyperosmolar agents.

C. Factors Influencing ICP & the Monro-Kellie Doctrine4 marks

Compartment	Compensatory Mechanism	Pathological Increase
CSF	Shunted to spinal subarachnoid space; increased reabsorption	Hydrocephalus, choroid plexus tumor
Blood	Venous compression/displacement (first, fastest buffer)	Venous sinus thrombosis, jugular compression, hypercapnia
Brain	Minimal - only via herniation (decompensation)	Tumor, edema, abscess

Normal ICP 5-15 mmHg (supine adult). CPP = MAP - ICP (or -CVP if higher). Target CPP in TBI: 60-70 mmHg (BTF).

Monro-Kellie Doctrine

Cranium is rigid/non-expansile. Total intracranial volume = Brain (80%) + CSF (10%) + Blood (10%) = constant. Increase in one compartment must be offset by another (CSF first, then venous blood) - once reserve is exhausted, the pressure-volume curve becomes exponential.

D. Pharmacological Strategies to Decrease Elevated ICP3 marks

Agent/Strategy	Mechanism	Practical Points
Mannitol 0.25-1 g/kg	Osmotic gradient draws water into vasculature	Onset 15-30min, lasts 90min-6h; needs intact BBB; risk rebound edema/AKI if osm >320
Hypertonic saline 3-23.4%	Osmotic effect without diuresis	Preferred if hypotensive/hypovolemic; monitor Na (avoid >160 or rapid correction)
Hyperventilation PaCO2 30-35	Hypocapnia -> vasoconstriction -> lower CBV	Temporizing only; avoid PaCO2 <25; reserve for impending herniation
Sedation (propofol/midazolam)	Lower CMRO2 -> lower CBF -> lower CBV	Watch hypotension/lower CPP
Barbiturate coma	Maximal CMRO2 reduction, burst suppression	Refractory ICP only; myocardial depression
Neuromuscular blockade	Prevents coughing/straining raising ICP	Adjunct only; masks seizures
Head-up 30 deg, neutral neck	Promotes jugular venous drainage	Avoid jugular compression from tight ETT ties
CSF drainage (EVD)	Direct volume removal	Most rapid, titratable ICP-lowering intervention
Decompressive craniectomy	Removes rigid-box constraint	Refractory ICP; improves survival (DECRA/RESCUEicp)

E. Continuous SjO2 Monitoring3 marks

Fiberoptic catheter retrogradely placed in the internal jugular vein (dominant side) with tip at the jugular bulb samples global cerebral venous oxygen saturation.

SjO2 Value	Interpretation
Normal 55-75%	Balanced CBF-CMRO2 coupling
<50% (desaturation)	Relative cerebral ischemia - inadequate CBF for demand
>75% (luxury perfusion)	Hyperemia OR reduced O2 extraction/mitochondrial failure

Limitation: global not regional - focal ischemia can be masked. Requires frequent co-oximetry calibration. Complements PbtO2 for regional data.

💬 Viva Corner

Q. What is the lower and upper limit of cerebral autoregulation?

MAP 60-150 mmHg in normotensive adults. Below 60: ischemia risk. Above 150: forced vasodilation, edema/hemorrhage risk. Curve shifts right in chronic hypertensives.

Q. Mannitol vs hypertonic saline in a hypotensive TBI patient?

Hypertonic saline - mannitol causes osmotic diuresis and can worsen hypovolemia/hypotension; HTS expands intravascular volume while reducing ICP.

★ Examiner's Pearl

Draw the autoregulation curve with numeric limits (60-150 mmHg). State Monro-Kellie quantitatively (80:10:10). For SjO2 always mention it is a global, not regional, measure.

References

Miller's Anesthesia 9th Ed Ch16/41. Brain Trauma Foundation Guidelines 4th Ed (2016). Smith M. Monitoring intracranial pressure (Anesth Analg 2008;106:240-248).

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 200 person Asked by .

bookmark_add

Functional anatomy of the NMJ; mechanism, metabolism, elimination kinetics, TOF/PTC-based dosing, and anaphylaxis/cardiac risk of Sugammadex.

description Clinical Response

"

Q2 · PAPER I · 10 MARKS

Neuromuscular Junction Anatomy & Clinical Pharmacology of Sugammadex

PGIMER · PAPER I — APPLIED BASIC SCIENCES [10 MARKS]

Functional anatomy of the NMJ; mechanism, metabolism, elimination kinetics, TOF/PTC-based dosing, and anaphylaxis/cardiac risk of Sugammadex.

⚙ Core Concept

Sugammadex is a modified gamma-cyclodextrin that reverses aminosteroid NMBs (rocuronium > vecuronium) by direct molecular encapsulation - not enzyme inhibition - allowing reversal of any depth of block, including immediate post-induction rescue.

A. Functional Anatomy of the NMJ

Component	Structure	Function
Presynaptic terminal	ACh vesicles (~10,000 molecules each), mitochondria, VG Ca2+ channels	AP -> Ca2+ influx -> vesicle fusion -> ACh release
Synaptic cleft	~50 nm gap; AChE anchored to basal lamina	ACh diffuses across; AChE terminates signal <1ms
Postsynaptic membrane	Junctional folds bearing nicotinic AChR at fold crests	ACh binding -> channel opens -> end-plate potential
Nicotinic AChR	Pentameric (2a,b,d,e - adult); 2 ACh must bind both alpha subunits	Basis of competitive antagonism by NDMRs

Large margin of safety - only 70-80% receptor occupancy needed to block transmission; ~75% must be blocked before twitch height visibly falls on TOF.

B. Mechanism - Encapsulation vs AChE Inhibition

Feature	Sugammadex (Encapsulation)	Neostigmine (AChE Inhibition)
Mechanism	Cyclodextrin forms 1:1 host-guest complex with rocuronium's steroid nucleus	Inhibits AChE -> raises ACh, out-competes NDMR
Selectivity	Aminosteroids only (roc>>vec>panc); ineffective vs benzylisoquinoliniums	Non-selective, effective on all NDMRs
Depth reversible	Any depth incl. profound block (PTC 1-2)	Only moderate block (>=2 TOF twitches)
Onset	Rapid 2-3 min even from deep block	Slower 10-15 min even from moderate block
Cholinergic effects	None	Bradycardia, bronchospasm, salivation - needs antimuscarinic
Ceiling effect	None within clinical doses	Yes - excess dose worsens block

C. Pharmacokinetics, Metabolism & Elimination

Distribution: Vd ~11-14 L
Metabolism: sugammadex itself is NOT metabolized, pharmacologically inert once bound
Elimination: free sugammadex and sugammadex-rocuronium complex eliminated almost entirely unchanged renally (>90% in 24h); t1/2 ~2h
Mechanism: encapsulation creates a concentration gradient drawing rocuronium from NMJ back to plasma (""Le Chatelier"")

Renal Impairment

Severe renal impairment (CrCl <30) markedly prolongs elimination of the complex - not recommended in dialysis/severe renal failure per several guidelines; use individualized.

D. Dosing Strategies (TOF/PTC)3 marks

Clinical Scenario	Depth of Block	Dose
Routine reversal	Reappearance of T2 on TOF	2 mg/kg IV
Deep block reversal	PTC 1-2 (no TOF response)	4 mg/kg IV
Immediate reversal	3 min after rocuronium 1.2 mg/kg (CICV rescue)	16 mg/kg IV

Endpoint of adequate reversal: quantitative TOF ratio >=0.9 on objective monitoring - tactile/visual assessment is unreliable above TOF 0.4.

E. Anaphylactic Risk & Cardiac Side Effects3 marks

Anaphylaxis: ~0.039-0.3% incidence (dose-dependent, higher with 16 mg/kg); NAP6 (UK) identified sugammadex as a significant trigger, can occur on first exposure
Cardiac: generally stable; bradycardia (including rare severe cases) - FDA warning to keep atropine available
Coagulation: mild transient aPTT/PT prolongation
Hormonal: transiently binds progesterone - advise additional contraception for 7 days

💬 Viva Corner

Q. Why can sugammadex reverse profound block when neostigmine cannot?

Neostigmine out-competes the relaxant via raised ACh but has a ceiling effect at profound block. Sugammadex physically removes rocuronium from circulation, independent of receptor occupancy.

Q. What is the objective endpoint for safe extubation after sugammadex?

Quantitative TOF ratio >=0.9 on an objective monitor - tactile/visual assessment cannot reliably distinguish TOF 0.4 from 0.9.

★ Examiner's Pearl

Contrast encapsulation vs AChE inhibition explicitly. Quote the three dosing scenarios (2/4/16 mg/kg) tied to TOF/PTC criteria, and mention NAP6 for anaphylaxis.

References

Naguib M. Sugammadex (Anesth Analg 2007;104:575-581). NAP6 Report, RCoA 2018. Hristovska AM et al. Cochrane 2017.

"

Emergency Medicine

General Medicine

Obstetrics & Gynaecology

Orthopedics

Pediatrics

Monthly

Quarterly

Half-Yearly (6 Months)

Yearly

Best Plan

Anesthesia

Coagulation Disorders & Transfusion in the ICU

Nutrition in the Critically Ill Patient

Multi-Organ Dysfunction Syndrome (MODS)

ICU-Acquired Infections & Antibiotic Stewardship

Neurological Monitoring & Brain Death

Cardiovascular Emergencies in the ICU

Common Poisoning & Drug Overdose Management

End-of-Life Care & Ethical Decision-Making in ICU

Discuss the physiological regulation of CBF, BBB structure/breakdown in neuro-trauma, ICP factors, ICP-lowering pharmacology, and SjO2 monitoring.

Functional anatomy of the NMJ; mechanism, metabolism, elimination kinetics, TOF/PTC-based dosing, and anaphylaxis/cardiac risk of Sugammadex.

Subcategory Tree

Category Subscription

Anatomical Models

Case Reviews